DNLI News and Press, Denali Therapeutics Inc. From 02/25/21

Denali Therapeutics (DNLI): Q4 GAAP EPS of $1.91 beats by $2.44.Revenue of $316.81M ($4.6M Y/Y) beats by $238.6M.Press Release For further details see: Denali Therapeutics EPS beats by $2.44, beats on revenue

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financi...

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target PR Newswire CAMBRIDGE, Mass. , Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life science...

Denali Therapeutics (DNLI) announces additional positive interim results from its ongoing Phase 1/2 study evaluating DNL310 as a potential brain-penetrant enzyme replacement therapy for treating both central nervous system ((CNS)) and peripheral manifestations of Hunter sy...

Sustained normalization and further decreased levels of CSF glycosaminoglycan heparan sulfate, a key CNS disease biomarker, observed after three months of intravenous dosing Reductions in exploratory CSF biomarkers consistent with improved lysosomal function Redu...

The following slide deck was published by Denali Therapeutics Inc. in conjunction with this event. For further details see: Denali Therapeutics (DNLI) Presents At J.P. Morgan 39th Annual Healthcare Conference - Slideshow

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced its pa...

High-scoring, high short-interest stocks that can benefit from ongoing short covering by hedge funds as they reduce single stock risk. Institutional quality stocks with potential catalysts that support ongoing short covering, rather than flash-in-the-pan volatility. Ideas across a...

F-star's antibody engineering platform is seemingly undervalued with comparable companies worth billions of dollars in equity value. The company has an exciting pipeline of early immuno-therapy clinical assets from F-star's recent pivot, 2 years ago, to internal drug development. ...